{"id":"target-inr-1-8","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"}]},"_chembl":{"chemblId":"CHEMBL3682150","moleculeType":"Small molecule","molecularWeight":"404.47"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"It likely modulates the coagulation pathway to achieve a balanced anticoagulant effect, ensuring that the blood's clotting tendency remains within a safe and effective range.","oneSentence":"The drug aims to maintain the International Normalized Ratio (INR) at 1.8 to prevent thrombosis while minimizing bleeding risk.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:37:31.979Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of thromboembolic events in patients with atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT01461889","phase":"PHASE3","title":"INR-Triggered Transfusion In GI Bleeders From ER","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2011-07","conditions":"Respiratory Distress Syndrome, Adult, Gastrointestinal Hemorrhage, Liver Diseases","enrollment":50},{"nctId":"NCT01006733","phase":"PHASE3","title":"Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-03","conditions":"Thromboembolism","enrollment":1598},{"nctId":"NCT00097357","phase":"PHASE2, PHASE3","title":"BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-10","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":1238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Target INR 1.8","genericName":"Target INR 1.8","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The drug aims to maintain the International Normalized Ratio (INR) at 1.8 to prevent thrombosis while minimizing bleeding risk. Used for Prevention of thromboembolic events in patients with atrial fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}